Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether
Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose
levels in response to an oral glucose tolerance test (OGTT).